A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective

References

• Carter MJ, Lobo AJ, Travis SPL; on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl V):v1-16
   PubMedGoogle Scholar
• Gibson TB, Ng E, Ozminkowski RJ, The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50:1261-1272
   PubMed Web of Science ®Google Scholar
• Actis GC, Pazienza P, Rosina F. Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm Allergy Drug Targets 2008;7:1-5
   PubMedGoogle Scholar
• Mezavant XL 1200mg, gastro-resistant, prolonged release tablets. Summary of Product Characteristics. Available from http://emc.medicines.org.uk
   Google Scholar
• Prantera C, Viscido A, Biancone L, A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005;11:421-427
   PubMed Web of Science ®Google Scholar
• Asacol 400mg MR tablets, Summary of Product Characteristics. Available from http://emc.medicines.org.uk
   Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P, Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102
   PubMed Web of Science ®Google Scholar
• Kamm MA, Sandborn WJ, Gassull M, Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132:66-75
   PubMed Web of Science ®Google Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ, Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2009;15:1-8
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (June 2008) Section 5.6.1 of Guide to the Methods of Technology Appraisal. Last accessed December 9, 2009: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
   Google Scholar
• Kane S, Huo D, Aikens J, Medication nonadherence and the outcomes of subjects with quiescent ulcerative colitis. Am J Med 2003;114:39-43
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Longmore AJ, Newell AC, An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1960;1:217
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11
   PubMed Web of Science ®Google Scholar
• Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23:577-585
   PubMed Web of Science ®Google Scholar
• Kane SV, Hanauer SB. National adherence rates with IBD therapy: PO vs PR. Am J Gastroenterol 2001;96:S296
   Google Scholar
• Kane SV, Sumner M, Solomon D, Twelve-month persistence with 5-aminosalicylic acid therapy: results from a large pharmacy database. Poster presented at the 40th Annual Digestive Disease Week, Chicago, IL, USA; May 30-June 4, 2009
   Google Scholar
• Shaya FT, El Khoury AC, Wong W, Persistence with pharmacotherapy for gastrointestinal disease: Associated costs of health care. P&T 2006;31:657-665
   Google Scholar
• Katsanos KH, Vermeire S, Christodoulou DK, Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 2007;75:113-121
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Card T, Logan RF, 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54:1573-1578
   PubMed Web of Science ®Google Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-1353
   PubMed Web of Science ®Google Scholar
• Carter MJ, Lobo AJ, Travis SPL; on behalf of the IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl V):v1-16
   PubMedGoogle Scholar
• Travis SPL, Stange EF, Lémann M, European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008;2:24-62
   Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535
   PubMed Web of Science ®Google Scholar
• Bowel Cancer Services: Costs and Benefits: York Health Economics Consortium & Scharr.:,2008
   Google Scholar
• British National Formulary (BNF). Available at www.bnf.org.uk. Accessed July, 2008
   Google Scholar
• Bassi A, Dodd S, Williamson P, Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-1478
   PubMed Web of Science ®Google Scholar
• Bassi A, Bodger K. Health state utilities & willingness-to-pay in inflammatory bowel disease (IBD) - a study of feasibility & validity. Aliment Pharmacol Ther 2005;21:197-198 (Abstract)
   Google Scholar
• Luces C, Brown E, Bodger K. Satisfaction with healthcare in inflammatory bowel disease: influence of patient characteristics. Gut 2007;56(Suppl 2):A145 (Abstract)
   Google Scholar
• Ness RM, Holmes AM, Klein R, utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999;94:1650-1657
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629
   PubMed Web of Science ®Google Scholar
• Sninsky CA, Cort DH, Shanchan E, Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicentre study. Ann Intern Med 1991;115:350-355
   PubMed Web of Science ®Google Scholar
• Yen E, Kane S, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 2008;103:1-12
   Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-1385
   PubMed Web of Science ®Google Scholar